In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Added individuals might be enrolled for the recognized monotherapy dosign program. In Section B, participants will get oral ruxolitinib and ABBV-744 will likely be provided as